Valvular disease: TAVR outcomes maintained 2-years after the PARTNER trial

Comment

Alexandra King. Nat Rev Cardiol. 2012.

. 2012 Apr 10;9(6):314.

doi: 10.1038/nrcardio.2012.56.

No abstract available

Comment on

Transcatheter aortic-valve replacement for inoperable severe aortic stenosis.
Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB; PARTNER Trial Investigators. Makkar RR, et al. N Engl J Med. 2012 May 3;366(18):1696-704. doi: 10.1056/NEJMoa1202277. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22443478 Clinical Trial.
Two-year outcomes after transcatheter or surgical aortic-valve replacement.
Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; PARTNER Trial Investigators. Kodali SK, et al. N Engl J Med. 2012 May 3;366(18):1686-95. doi: 10.1056/NEJMoa1200384. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22443479 Clinical Trial.